FP7Reintegration grant2011–2014

RIMINCGD · Regulation of Inflammation by Macrophages in Chronic Granulomatous Diseases

FP7 — People (Marie Curie Actions)

Duration
2011-03-01 → 2014-02-28
EU contribution
€75,000
Participants
1
Scheme
MC-IRG

Lines connect the coordinator with its partners.

Results in brief

Regulation of Inflammation by Macrophages in Chronic Granulomatous Diseases

Chronic granulomatous disease (CGD) is a primary immunodeficiency caused by the genetic deficiency of NADPH oxidase. Patients with CGD suffer from recurrent life-threatening infections, consistent with the importance of NADPH oxidase for the induction of respiratory burst in macrophages and neutrophils. Another aspect of this disorder is a state of hyperinflammation, which leads to excessive persistent granulomatous responses. Granulomas are histologically defined areas of tissue inflammation which contain neutrophils and necrotic tissue surrounded by macrophages and multinucleated giant cells. The formation of granulomas is important for immune defence against pathogens, such as mycobacteria. However in CGD, granulomas can be sterile, destruct normal tissue and often lead to life-threatening complications such as granulomatous bowel obstruction. The mechanisms of hyperinflammatory granuloma formation in CGD as well as in other immune diseases with chronic granuloma formation, such as Crohn’s disease and sarcoidosis, are poorly understood. The goal of this project was to elucidate these mechanisms. Our work has been focused on the role of macrophages, as major components of granulomatous responses. Macrophages are known to be important for mycobacterial granuloma formation, since Pu.1 deficiency suppresses granuloma formation (Clay H, Ramakrishnan L, Cell Host Microbe 2007), and TNF-dependent macrophage survival is likewise significant for the maintenance and dissemination of granulomas (Clay H, Ramakrishnan L, Immunity 2008). In granulomas, macrophages appear enlarged and sometimes contain several nuclei, thus giving rise to the terms ‘epithelioid macrophages’ and ‘multinucleated giant cells’ respectively. Multinucleated giant cells express proteases such as MMP9 which are thought to be crucial for granuloma organization. How macrophages increase their size in the context of granuloma formation remains largely unknown. We have shown that macrophages can grow by polyploidization in response to mycobacteria or purified TLR ligands in vitro and in the context of Mycobacterium bovis granuloma formation in vivo. Using long term live cell imaging we found that in response to TLR2 ligands, multinucleation and polyploidization results from recurrent cytokinesis failure and re-programming of cell cycle regulators such as the transcription factors MafB/Myc. In summary, we found a pathway of macrophage polyploidization and multinucleated giant cell formation which is distinct from the previously described cytokine-induced macrophage multinucleation by cell-to-cell fusion. We propose that macrophage growth by pathogen-mediated cell cycle regulation and polyploidization may be an important mechanism for the maintenance of granulomas during immunity to mycobacterial infection or autoimmune hyperinflammation. This work may thus lead to the development of new therapeutic strategies for hyperinflammatory granulomatous responses.

Data: CORDIS, © European Union

Project objective

Chronic granulomatous disease (CGD) affects children and young adults and is associated with significant morbidity, mortality and socio-economic costs. CGD is caused by the genetic deficiency of NADPH oxidase (Nox). The characteristic lesion in CGD is the development of granulomas, or confined areas of tissue inflammation, which are characterized by the presence of macrophages (Mph) and Mph-derived multinucleated giant cells. Granulomas physiologically function to wall off microorganisms or foreign bodies. In CGD, however, granulomas persist in the absence of detectable microorganisms, thus causing severe life-threatening complications. We hypothesize that Nox deficiency results in hyperinflammation due to a Mph-intrinsic defect. The goals of this study are 1. to determine the role of ‘inflammatory’ monocytes in granuloma formation in the Nox2-/- CGD mouse model using a loss-of-function and adoptive transfer approach and 2. to analyze mechanisms by which Nox deficiency suppresses ‘anti-inflammatory’ macrophage functions that physiologically control hyperinflammation and mediate tissue repair, using genetic and molecular biology approaches. The second goal will be accomplished in collaboration with Dr. Lionel Ivashkiv (New York). Eventually, these studies aim at the identification of new Mph-specific treatment modalities for CGD. Funding of this proposal will allow the applicant to develop an independent area of research in the hosting Centre for Chronic Immunodeficiency (CCI) in Freiburg, Germany and will thus give her the chance to establish herself as an independent investigator in Europe. The hosting CCI will benefit from the applicant’s scientific and technical expertise in macrophage activation in inflammatory diseases. Integrating the applicant into the CCI will further serve as a starting point of a long lasting collaboration with the internationally renowned group on macrophage signaling and inflammation headed by Dr Lionel Ivahskiv.

Original text from CORDIS.

Participants

  • UNIVERSITAETSKLINIKUM FREIBURG · FreiburgCoordinatorGermany

Links

Data: CORDIS, © European Union